Ardent Health Partners Inc. has announced its financial results for the first quarter of 2025, reporting a total revenue of $1.50 billion, marking a 4.0% growth compared to the same period in the previous year. The company's net income attributable to Ardent Health reached $41 million, translating to $0.29 per diluted share, showing an increase from $27 million, or $0.21 per diluted share, in the first quarter of 2024. Adjusted EBITDA experienced a 2.5% increase year-over-year, reaching $98 million. In terms of admissions, Ardent Health reported a 7.6% growth year-over-year, totaling 41,389 admissions, while adjusted admissions rose by 2.7% to 84,536. However, outpatient surgeries saw a slight decline of 2.3%. The company has reaffirmed its full-year 2025 financial guidance, projecting total revenue between $6.2 billion and $6.45 billion and net income attributable to Ardent Health between $245 million and $285 million. Adjusted EBITDA is expected to be in the range of $575 million to $615 million. The company's guidance also anticipates adjusted admissions growth between 2.0% and 3.0%. Ardent Health continues to focus on operational excellence, achieving a reduction in supply costs and moderating the growth of professional fee expenses. The company is exploring inorganic growth opportunities, leveraging its strong balance sheet to pursue value-enhancing transactions and expressing interest in its joint venture model.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.